Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by ARS Pharmaceuticals, Inc. (SPRY)Accesswire • 03/13/24
Levi & Korsinsky Reminds Shareholders of an Investigation into ARS Pharmaceuticals, Inc. (SPRY) Regarding Potential Securities Fraud AllegationsAccesswire • 03/12/24
Shareholder Rights Advocates at Levi & Korsinsky Investigate ARS Pharmaceuticals, Inc. (SPRY) Regarding Possible Securities Fraud ViolationsAccesswire • 03/08/24
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayGlobeNewsWire • 03/07/24
Lost Money on ARS Pharmaceuticals, Inc.(SPRY)? You May Have Been Affected by Fraud - Contact Levi & KorsinskyAccesswire • 03/07/24
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024GlobeNewsWire • 03/06/24
ATTENTION SPRY SHAREHOLDERS: Investors who lost money on ARS Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigationAccesswire • 03/06/24
ARS Being Investigated on Behalf of ARS Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For DetailsAccesswire • 03/05/24
ARS Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SPRYAccesswire • 03/04/24
Levi & Korsinsky Announces an Investigation on Behalf of ARS Pharmaceuticals, Inc. (SPRY) Shareholders Who May Have Been Affected by FraudAccesswire • 02/27/24
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical studyGlobeNewsWire • 02/26/24
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response LetterGlobeNewsWire • 02/20/24
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual MeetingGlobeNewsWire • 02/05/24
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 01/17/24
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/09/23
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisGlobeNewsWire • 11/09/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 11/09/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 11/07/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 10/22/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 10/16/23
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)GlobeNewsWire • 10/06/23
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical ImmunologyGlobeNewsWire • 10/03/23
